Zhejiang Tailin BioEngineering Co.,Ltd (SHE:300813)
China · Delayed Price · Currency is CNY 20.48
+0.23 (1.14%)
Aug 14, 2026, 3:04 PM CST
SHE:300813 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 342.66 | 339.54 | 349 | 269.86 | 373.88 | 283.25 |
Revenue Growth | 2.00% | -2.71% | 29.33% | -27.82% | 32.00% | 41.46% |
Gross Profit Gross Profit Growth | 152.61 | 150.34 | 151.14 | 127.86 | 193.57 | 171.43 |
Operating Income Operating Income Growth | 8.56 | 5.82 | 11.81 | 2.77 | 63.78 | 57.82 |
Net Income Net Income Growth | 17.8 | 16.49 | 13.05 | 19.67 | 79.69 | 63.53 |
Earnings Per Share EPS Growth | 0.15 | 0.14 | 0.12 | 0.17 | 0.71 | 0.58 |
EPS Growth | 52.49% | 16.67% | -29.41% | -76.06% | 21.45% | 28.01% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Pharmaceutical Industry Pharmaceutical Industry Growth | 311.76 | 308.64 | 314.25 | 236.32 | 345 | 253.64 |
Unallocated Other Industries Unallocated Other Industries Growth | - | 30.9 | 34.75 | 33.54 | 28.88 | 29.61 |
Total Total Growth | 342.66 | 339.54 | 349 | 269.86 | 373.88 | 283.25 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 338.81 | 332.6 | 399.84 | 396.98 | 577.15 | 322.51 |
Total Debt Total Debt Growth | - | - | 3.67 | 157.59 | 145.47 | 7.21 |
Net Cash (Debt) Net Cash Growth | 338.81 | 332.6 | 396.17 | 239.39 | 431.69 | 315.3 |
Net Cash Growth | 61.08% | -16.05% | 65.49% | -44.55% | 36.91% | -2.13% |
Net Cash Per Share Net Cash Per Share Growth | 2.86 | 2.82 | 3.64 | 2.07 | 3.85 | 2.90 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 54.9 | 47.72 | 24.66 | 1.93 | 89.39 | 35.96 |
Capital Expenditures CapEx Growth | -54.67 | -46.89 | -18.54 | -176.24 | -29.14 | -25.91 |
Free Cash Flow Free Cash Flow Growth | 0.23 | 0.84 | 6.12 | -174.31 | 60.24 | 10.05 |
Free Cash Flow Growth | -97.48% | -86.33% | - | - | 499.36% | -89.87% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 44.54% | 44.28% | 43.31% | 47.38% | 51.77% | 60.52% |
Operating Margin | 2.50% | 1.71% | 3.38% | 1.03% | 17.06% | 20.41% |
Pretax Margin | 5.40% | 4.93% | 3.66% | 8.14% | 21.38% | 24.59% |
Profit Margin | 5.19% | 4.86% | 3.74% | 7.29% | 21.31% | 22.43% |
FCF Margin | 0.07% | 0.25% | 1.75% | -64.59% | 16.11% | 3.55% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.030 | 0.030 | 0.100 | 0.100 | 0.231 | 0.144 |
Dividend Per Share Growth | 30.00% | -70.00% | 0% | -56.67% | 59.95% | 50.00% |
Dividend Yield | 0.15% | 0.12% | 0.58% | 0.41% | 0.66% | 0.31% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 136.48 | 178.84 | 160.38 | 135.48 | 48.48 | 81.80 |
P/FCF Ratio | 10615.64 | 3524.81 | 342.09 | - | 64.13 | 517.06 |
PS Ratio | 7.24 | 8.68 | 6.00 | 9.88 | 10.33 | 18.35 |